Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.
Guillaume BeziatLoic YsebaertPublished in: OncoTargets and therapy (2020)
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare myeloid malignancy, for which conventional chemotherapy has poor outcomes. CD123, the α-subunit of interleukin (IL)-3 receptor, is constantly overexpressed at the surface of tumoral cells. Tagraxofusp (or SL-401) is a recombinant cytotoxin which consists of human interleukin-3 fused to a truncated diphtheria toxin. It is currently the only novel therapy with a prospective evaluation of efficacy and safety in the treatment of BPDCN and is also the only one to achieve FDA approval. In this short review, the results of tagraxofusp are summarized and perspectives of its use in BPDCN and in other malignancies are discussed. The safety profile is also summarized, since capillary leak syndrome is the main toxic effect of the drug, along with more common toxicities including an increase in transaminases and thrombocytopenia.
Keyphrases
- dendritic cells
- regulatory t cells
- immune response
- escherichia coli
- endothelial cells
- induced apoptosis
- type diabetes
- low grade
- emergency department
- squamous cell carcinoma
- machine learning
- acute myeloid leukemia
- electronic health record
- cell cycle arrest
- mesenchymal stem cells
- combination therapy
- signaling pathway
- skeletal muscle
- locally advanced
- bone marrow
- binding protein
- artificial intelligence
- rectal cancer
- nk cells
- glycemic control